<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727282</url>
  </required_header>
  <id_info>
    <org_study_id>VTI-TAPSE</org_study_id>
    <nct_id>NCT03727282</nct_id>
  </id_info>
  <brief_title>Left Ventricular Volume Index in the Adjustment of Initial Dose of Dobutamine in Heart Failure and Cardiogenic Shock</brief_title>
  <official_title>Use of Transtoracic Ecocargiogram With Calculation of Left Ventricular Volume Index in the Initial Adjustment of Initial Dose of Dobutamine in Patients With Heart Failure and Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have suggested that the use of left ventricular ejection volume index
      calculation may aid in the hemodynamic management of critically ill patients. However, a
      prospective and randomized comparison in patients with heart failure for inotropic dose
      adjustment has not been described. The objective of this study was to evaluate the efficacy
      and safety of ejection volume index versus liberal strategy in adjusting dobutamine dose in
      patients with heart failure and low cardiac output. Methodology: A unicentric, randomized and
      prospective study will be performed in a comparative manner. Hospital data (test results,
      medical outcomes, dobutamine dose, complications) of patients will be analyzed for safety and
      effectiveness. Expected results: The use of ejection volume index is not inferior to the
      liberal strategy in the initial adjustment of the dose of dobutamine in patients with heart
      failure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2019</start_date>
  <completion_date type="Anticipated">January 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>base excess levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bicarbonate levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>physical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac output</measure>
    <time_frame>24 hours</time_frame>
    <description>echocardiography echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic volume</measure>
    <time_frame>24 hours</time_frame>
    <description>echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary output</measure>
    <time_frame>24 hours</time_frame>
    <description>urine analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial lactate levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>central venous oxygen saturation levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BNP levels</measure>
    <time_frame>24 hours</time_frame>
    <description>plasma analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>troponin levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate</measure>
    <time_frame>24 hours</time_frame>
    <description>physical evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urea levels</measure>
    <time_frame>24 hours</time_frame>
    <description>serum analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurrence of sustained ventricular arrhythmia</measure>
    <time_frame>24 hours</time_frame>
    <description>electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for orotracheal intubation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for vasopressor or other inotropic association</measure>
    <time_frame>24 hours</time_frame>
    <description>hipotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for mechanical circulatory assistance</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lowering of consciousness level</measure>
    <time_frame>24 hours</time_frame>
    <description>glasgow &lt; 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiorespiratory arrest</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening of renal function</measure>
    <time_frame>24 hours</time_frame>
    <description>increase 0.5 mg / dl in relation to admission creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure of dobutamine weaning up</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization time</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Liberal strategy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ejection volume index</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjust dobutamine according to the ejection volume index</intervention_name>
    <description>adjust dobutamine dose</description>
    <arm_group_label>ejection volume index</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjust dobutamine according to the attending physician</intervention_name>
    <description>adjust dobutamine dose</description>
    <arm_group_label>Liberal strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF ≤ 40% documented on echocardiography

          -  BNP&gt; 500 pg / mL

          -  Need for initiation of dobutamine and signs or symptoms of low cardiac output at
             admission defined by the presence of 2 or more of the following:

               -  SBP ≤ 95 mmHg

               -  FC&gt; 100 bpm

               -  Peripheral vasoconstriction,

               -  Cold extremities,

               -  Reference of decrease of urine output,

               -  Nausea, vomiting and food intolerance,

               -  Presence of organic dysfunction

        Exclusion Criteria:

          -  Pregnancy.

          -  COPD

          -  Hepatical cirrhosis

          -  Atrioventricular block of 2nd or 3rd degree. and. SBP &lt;80 mmHg or need for
             vasopressor.

          -  Use of definitive pacemaker.

          -  Body mass index greater than 40 kg / m2.

          -  Use of oral anticoagulant.

          -  Acute coronary syndrome.

          -  Indication of use of another inotropic other than dobutamine.

          -  Orotracheal intubation.

          -  Presence of significant pericardial effusion.

          -  Obstruction of left ventricular outflow tract.

          -  Serum creatinine&gt; 5.0 mg / dL or hemodialysis.

          -  Presence of 2 or more clinical / laboratory / radiological criteria of infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mucio Tavares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Clínica de Emergência</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Soeiro, MD</last_name>
    <phone>1126615299</phone>
    <email>alexandre.soeiro@bol.com.br</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

